NetraMark
Healthcare Software · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1655 Dupont St Ste 101, Toronto, Ontario...Phone Number
(403) 681-2549Website
www.netramark.comRevenue
<$5 MillionStock Symbol
AIAIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
2
2
1
1
About NetraMark
NetraMark specializes in advanced AI solutions designed to enhance clinical trial development processes. Their flagship product, NetraAI, utilizes innovative technology to provide insights into patient populations, optimizing study design and improving trial efficacy. The company also offers solutions like NetraPlacebo and NetraGPT, which leverage data to understand placebo responses and enhance explainability, respectively. Target clients include clinical trial professionals and sponsors looking to improve trial outcomes through data-driven insights.Explore more
NetraMark Org Chart
SK
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NetraMark your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on NetraMark recently announced quarterly report
Website visits: Recent activity has been detected on your website
NetraMark, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if NetraMark had a recent Job posting/layoffs
Product Launch: Get notified when NetraMark launches new products
Funding: Get notified immidiatlly once NetraMark has new funding data
Congratulate Masked Content for being promoted to Masked Content at NetraMark
Check if NetraMark has recently received funding, and reach out quickly before it becomes old news!
Check out if NetraMark is spiking on competitors!
Recommended Actions
Find VP level buyers at NetraMark
Find more new buyers
Compare Similar Companies to NetraMark
Compare insights from companies similar to NetraMark, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NetraMark is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
NetraMark is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about NetraMark.
NetraMark financials insights
Gather financial insights about NetraMark, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$2.5M
NetraMark Tech Stack
A closer look at the technologies used by NetraMark
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Project
Clinical Operations, Contracts
Project
Analytics & Insights, Research & Development, Medical Research, Clinical Operations, Contracts
NetraMark News & Media
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.NetraMark Announces Change To Board Of Directors
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy has resigned from the Company’s Board of Directors, effective May 7, 2026, for personal reasons.NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, as Fractional Chief Medical Officer, marking an important step in the Company’s evolution as it advances toward broader globaNetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that senior management will open the market at the Toronto Stock Exchange on May 5, 2026.
Read more news
Top Healthcare Software Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding NetraMark
Sign Up For FreeTo access detailed company insights
NetraMark specializes in advanced AI solutions designed to enhance clinical trial development processes. Their flagship product, NetraAI, utilizes innovative technology to provide insights into patient populations, optimizing study design and improving trial efficacy. The company also offers solutions like NetraPlacebo and NetraGPT, which leverage... Read More
